The risk of hospitalisation for acute kidney injury (AKI) appears to be lower after initiation of dapagliflozin than after initiation of other antihyperglycaemics in patients with type 2 diabetes mellitus (T2DM), according to findings of an AstraZeneca-funded study published in Drug Safety. …
